JPS5890599A - ステロイド化合物 - Google Patents

ステロイド化合物

Info

Publication number
JPS5890599A
JPS5890599A JP57181500A JP18150082A JPS5890599A JP S5890599 A JPS5890599 A JP S5890599A JP 57181500 A JP57181500 A JP 57181500A JP 18150082 A JP18150082 A JP 18150082A JP S5890599 A JPS5890599 A JP S5890599A
Authority
JP
Japan
Prior art keywords
monohydrate
water
beclomethasone
beclomethasone dipropionate
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP57181500A
Other languages
English (en)
Japanese (ja)
Other versions
JPH0424358B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html
Inventor
ジヨン・ハロルド・ハント
ジヨン・マルコム・パツドフイ−ルド
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JPS5890599A publication Critical patent/JPS5890599A/ja
Publication of JPH0424358B2 publication Critical patent/JPH0424358B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
JP57181500A 1981-10-19 1982-10-18 ステロイド化合物 Granted JPS5890599A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8131425 1981-10-19
GB8131425 1981-10-19

Publications (2)

Publication Number Publication Date
JPS5890599A true JPS5890599A (ja) 1983-05-30
JPH0424358B2 JPH0424358B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-24

Family

ID=10525238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP57181500A Granted JPS5890599A (ja) 1981-10-19 1982-10-18 ステロイド化合物

Country Status (22)

Country Link
US (1) US4866051A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5890599A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR890000664B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU551471B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE894725A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1189853A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH652134A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3238569A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK168389B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP1990004774A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8404374A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI73128C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2514769B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK100989A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE54170B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1196553B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY8700910A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL8204013A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ202212A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT75692A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE454356B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA827601B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002531390A (ja) * 1998-12-01 2002-09-24 アベンティス・フアーマ・リミテッド 微粉砕医薬物質を製造するための粉砕方法
JPWO2004046163A1 (ja) * 2002-11-08 2006-03-16 株式会社カネカ エルゴステロールの分離方法
JP2008031184A (ja) * 1994-01-27 2008-02-14 Schering Corp 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
JP2011518141A (ja) * 2008-04-16 2011-06-23 ブレス リミテッド ステロイドのネブライザー製剤

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766573A (en) * 1988-12-06 1998-06-16 Riker Laboratories, Inc. Medicinal aerosol formulations
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5208226A (en) * 1989-09-08 1993-05-04 Glaxo Group Limited Medicaments
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
SE9101090D0 (sv) * 1991-04-11 1991-04-11 Astra Ab Process for conditioning of water-soluble substances
GB9202519D0 (en) * 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
NZ257212A (en) 1992-09-29 1996-11-26 Inhale Therapeutic Syst Parathyroid hormone formulations comprising a biologically active n-terminal fragment of the hormone
GB9322014D0 (en) * 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
PT748213E (pt) 1994-03-07 2004-08-31 Nektar Therapeutics Metodos e composicoes para administracao pulmonar de insulina
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
AU6290396A (en) * 1995-06-29 1997-01-30 Mcneil-Ppc, Inc. The combination of topical nasal mast cell stabilizers and topical nasal steroids
US5987746A (en) * 1996-02-21 1999-11-23 Medtronic, Inc. Method of making medical electrical lead
US20030203036A1 (en) * 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
EP2280021B1 (en) * 1999-06-29 2016-02-17 MannKind Corporation Pharmaceutical formulations comprising insulin complexed with a diketopiperazine
PT1280520E (pt) 2000-05-10 2014-12-16 Novartis Ag Pós à base de fosfolípidos para administração de fármacos
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
US20020076382A1 (en) * 2000-08-04 2002-06-20 Kaplan Leonard W. Formulations of mometasone and a bronchodilator for pulmonary administration
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US8524279B2 (en) 2001-11-01 2013-09-03 Novartis Ag Spray drying methods and related compositions
DK1458360T3 (da) 2001-12-19 2011-08-29 Novartis Ag Pulmonær afgivelse af aminoglycosider
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
WO2005067964A1 (en) * 2004-01-12 2005-07-28 Mannkind Corporation A method of reducing serum proinsulin levels in type 2 diabetics
US20080090753A1 (en) * 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
MX2007001903A (es) 2004-08-20 2007-08-02 Mannkind Corp Catalisis de sintesis de dicetopiperazina.
ES2540853T3 (es) 2004-08-23 2015-07-14 Mannkind Corporation Sales de dicetopiperazina para la administración de fármacos
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
US20090186088A1 (en) * 2005-03-18 2009-07-23 Nanomaterials Technology Pte Ltd Inhalable drug
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
RU2403059C2 (ru) 2006-02-22 2010-11-10 Маннкайнд Корпорейшн Способ улучшения фармацевтических свойств микрочастиц, содержащих дикетопиперазин и активный агент
CA2649109A1 (en) * 2006-04-12 2007-10-25 Biodel, Inc. Rapid acting and long acting insulin combination formulations
UY30542A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de agonistas beta
UY30543A1 (es) * 2006-08-18 2008-03-31 Boehringer Ingelheim Int Formulacion de aerosol para la inhalacion de beta- agonistas
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
CN101951957A (zh) * 2008-01-04 2011-01-19 百达尔公司 胰岛素释放作为组织的葡萄糖水平的函数的胰岛素制剂
MY155524A (en) 2008-06-13 2015-10-30 Mannkind Corp A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
US9358352B2 (en) 2008-06-13 2016-06-07 Mannkind Corporation Dry powder drug delivery system and methods
BR122020002400B1 (pt) 2008-06-20 2021-12-07 Mannkind Corporation Sistema de detecção de inalação de pó seco e sistema de monitoramento acoplável para um inalador de pó seco
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
GB0914231D0 (en) * 2009-08-14 2009-09-30 Breath Ltd Dry powder inhaler formulations
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
AU2012236150B2 (en) 2011-04-01 2016-03-31 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
BR112014009686A2 (pt) 2011-10-24 2018-08-07 Mannkind Corp composição analgésica inalável, pó seco e método para tratar dor
CN108057154B (zh) 2012-07-12 2021-04-16 曼金德公司 干粉药物输送系统和方法
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
JP6491658B2 (ja) 2013-07-18 2019-03-27 マンカインド コーポレイション 熱安定性乾燥粉末医薬組成物及び方法
CN105517607A (zh) 2013-08-05 2016-04-20 曼金德公司 吹入设备和方法
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11756656B2 (en) 2018-06-14 2023-09-12 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
IT201800007527A1 (it) * 2018-07-26 2020-01-26 Sofar Spa Composizione contenente beclometasone per la prevenzione e il trattamento di prostatiti batteriche e vaginiti

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047519A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
CH622811A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1974-03-27 1981-04-30 Plurichemie Anstalt
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
ATE3774T1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, verfahren zu ihrer herstellung und herstellung einer formulierung.
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
PT71309A (en) * 1980-05-27 1980-06-01 Hovione Sociedade Quimica Lda Process of selective
PT73772B (en) * 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
US4391755A (en) * 1982-01-18 1983-07-05 E. R. Squibb & Sons, Inc. Steroid monohydrates, formulations containing same and method
US4913892A (en) * 1984-07-25 1990-04-03 Hovione Inter Ltd. Preparation and use of new solvates of beclomethasone 17,21-dipropionate
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008031184A (ja) * 1994-01-27 2008-02-14 Schering Corp 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
JP2008285497A (ja) * 1994-01-27 2008-11-27 Schering Corp 気道流路および肺疾患の処置のためのモメタゾンフロエートの使用
JP2002531390A (ja) * 1998-12-01 2002-09-24 アベンティス・フアーマ・リミテッド 微粉砕医薬物質を製造するための粉砕方法
JPWO2004046163A1 (ja) * 2002-11-08 2006-03-16 株式会社カネカ エルゴステロールの分離方法
JP4532281B2 (ja) * 2002-11-08 2010-08-25 株式会社カネカ エルゴステロールの分離方法
JP2011518141A (ja) * 2008-04-16 2011-06-23 ブレス リミテッド ステロイドのネブライザー製剤

Also Published As

Publication number Publication date
IE822514L (en) 1983-04-19
CA1189853A (en) 1985-07-02
SE454356B (sv) 1988-04-25
KR890000664B1 (ko) 1989-03-22
IT1196553B (it) 1988-11-16
US4866051A (en) 1989-09-12
BE894725A (fr) 1983-04-18
ES516611A0 (es) 1984-05-01
FI823561A0 (fi) 1982-10-18
FI823561L (fi) 1983-04-20
FR2514769A1 (fr) 1983-04-22
DE3238569A1 (de) 1983-05-05
DOP1990004774A (es) 1996-02-02
PT75692A (en) 1982-11-01
FR2514769B1 (fr) 1985-08-30
MY8700910A (en) 1987-12-31
DK168389B1 (da) 1994-03-21
IE54170B1 (en) 1989-07-05
ES8404374A1 (es) 1984-05-01
IT8249294A0 (it) 1982-10-18
ZA827601B (en) 1983-09-28
KR840002007A (ko) 1984-06-11
DE3238569C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-01-31
AU551471B2 (en) 1986-05-01
DK461182A (da) 1983-04-20
FI73128C (fi) 1987-09-10
JPH0424358B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-04-24
NL8204013A (nl) 1983-05-16
FI73128B (fi) 1987-05-29
SE8205904D0 (sv) 1982-10-18
CH652134A5 (de) 1985-10-31
SE8205904L (sv) 1983-04-20
NZ202212A (en) 1986-01-24
AU8946082A (en) 1984-05-03
HK100989A (en) 1989-12-29

Similar Documents

Publication Publication Date Title
JPS5890599A (ja) ステロイド化合物
US4414209A (en) Micronized aerosol steroids
US4044126A (en) Steroidal aerosol compositions and process for the preparation thereof
JP3729847B2 (ja) 新規結晶形態のビタミンｄ類似体
KR100799432B1 (ko) 신규 조성물
TWI248938B (en) Macrolides
JPS62501706A (ja) エアゾル用に適するよう物理的に修正されたベクロメタソンジプロピオネ−ト
EP0039369A1 (en) Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
GB2107715A (en) Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
MXPA05006441A (es) Preparacion de suspensiones acuosas esteriles que comprenden ingredientes activos cristalinos micronizados para inhalacion.
CA1075228A (en) Flunisolide to treat respiratory diseases
EP0513671A1 (en) Commiphora mukul extracts and therapeutical applications thereof
CN114206878A (zh) 乌帕替尼的晶型及其制备方法和用途
US4086254A (en) Photocleavable steroids
US4007268A (en) Process for alleviating proliferative skin diseases
US4211770A (en) Treatment of psoriasis intralesionally with N6 -2'-O-dibutyryl cyclic AMP
CZ282996B6 (cs) Hydroxynaftoát 4-hydroxy-alfa1-///6-(4-fenylbutoxy)hexyl/-amino/methyl/-1,3-benzendimethanolu, vhodný pro mikronisaci
MXPA04009338A (es) Formulaciones de un anhidrato en suspension con hfa.
JPH0412280B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
US3857941A (en) Pharmaceutical compositions and use of prednisolone 17-benzoate
GB2054600A (en) Halogenated 16-methyl-pregnane derivative
JPH0448B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN113980042A (zh) Crisaborole的晶型及其制备方法和用途
JPH0129199B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)